The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.
Bioharmony Therapeutics is developing novel, “lysin-based” antimicrobials. The company is out to change the world of antibiotics, not by tweaking an old formula, but by advancing an entirely new mode of action.
Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.
Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.
At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.
Since launching our Companies To Watch section in 2012 we have covered more than 50 companies. This year we plan to periodically look back at some of them and see where they are today.
Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”
Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical-stage development of its lead compound for treating MS and IBD.
“We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”
Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).
Pfizer’s top scientist, Mikael Dolsten, M.D., Ph.D., talks about being hyper focused during company’s R&D turnaround amongst CEO turnover, company integrations and M&A.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.
Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.